login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Encouraging early clinical results with Woven Endobridge cerebral aneurysm device


Friday, 16 Dec 2011 12:53

Flow diversion is a new approach for the endovascular treatment of intracranial aneurysms. The Woven Endobridge (WEB II, from Sequent Medical) cerebral aneurysm embolization device is an intrasaccular, oblate, braided-wire designed to provide flow disruption at the aneurysm neck-parent artery interface. A new study suggests that early data from the first two patients treated with the device is hopeful. 


A study published in August 2011 in the journal Neuroradiology suggests that the intrasaccular deployment of self-expanding, compliant, cylindrical, high-density, braided metallic mesh constructs could represent a reasonable approach as an endovascular treatment of cerebral aneurysms.


Investigators Joachim Klisch, Department of Diagnostic and Interventional Radiology and Neuroradiology, Helios General Hospital, Erfurt, Germany, and colleagues set out to evaluate the acute and short-term performance of the WEB II device regarding the immediacy, degree, and durability of aneurysm occlusion in two patients.


Klisch et al implanted the WEB II device in one patient with an unruptured middle cerebral artery trifurcation aneurysm and in another with an unruptured basilar tip aneurysm. They then graded the degree of intra-aneurysmal flow disruption based on serial digital subtraction aneurysm angiography performed over 30 min immediately following device implantation and at eight weeks. The team also performed immediate and eight-week post-treatment CT and 3-T MRI studies.


The authors wrote in the journal, “Delivery and deployment of the WEB II device was technically straightforward and achieved without complications.” Further, they noted that neither of the two devices required retrieval or repositioning after full deployment and there were no periprocedural thrombembolic or haemorrhagic complications. “In both cases, complete aneurysm occlusion was observed within minutes of device deployment. Short-term angiographic follow-up confirmed stable complete occlusion at eight weeks,” they noted. The authors also recommended in the paper that further clinical studies and long-term follow-up with the device should be pursued.


Tom Wilder, president and CEO of Sequent Medical told NeuroNews, “Sequent Medical is conducting a controlled release of the WEB Aneurysm Embolization system, which bears the CE mark, at a number of selected centres in Europe in order to gain further clinical experience. The company intends to initiate a number of clinical studies during 2012.”

 




Add New Comment

Most popular


MR CLEAN: expert opinion
Tuesday, 18 Nov 2014
Since the first presentation of data at the World Stroke Congress, the MR CLEAN trial has sent a ripple across the entire neurointerventional arena, raising questions about the future of stroke ... MR CLEAN: expert opinion

First patient treated in US pivotal trial evaluating cerebral protection during TAVI
Thursday, 09 Oct 2014
The randomised controlled SENTINEL Trial is the first in the USA to study capture and removal of debris released during TAVI that may otherwise be the source of stroke. First patient treated in US pivotal trial evaluating cerebral protection during TAVI

New Envoy catheters launched
Saturday, 11 Oct 2014
Codman Neuro has announced the Europe, Middle East and Africa launch of the Envoy DA XB Distal Access Guiding Catheter and the 7F Envoy Guiding Catheter for neurovascular procedures. New Envoy catheters launched

Features


The changing face of traumatic brain injury: Life beyond the guidelines
Tuesday, 18 Nov 2014
András Büki and Andrew Maas write that despite considerable efforts both in basic and clinical research, there has not been a major breakthrough in the care of the head injured in the last three ... The changing face of traumatic brain injury: Life beyond the guidelines

Neuro-oncologic treatment for glioblastoma
Monday, 21 Jul 2014
Malignant gliomas are the most common type of primary malignant brain tumour, accounting for 80% of patients and an annual incidence of 5.26 per 100,000 population, or 17,000 new cases diagnosed per ... Neuro-oncologic treatment for glioblastoma

Profiles


Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Mauricio Castillo
Monday, 14 Jul 2014
Mauricio Castillo is a professor of Radiology and chief, Division of Neuroradiology, University of N... Mauricio Castillo

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions